Skip to main content

Latent viruses in human genome

Latent viruses in human genome inspire novel directions for kidney cancer immunotherapy


Dana-Farber investigators found that normally defunct viral genes that lie dormant in the human genome can be activated in the most common form of kidney cancer (clear cell renal cell carcinoma) and can end up triggering an immune response against the cancer. The human genome contains viral DNA that was integrated into the genomic code long ago. A subset of these viral genes can still be reactivated under certain circumstances to produce viral proteins.

Published in Cell, this study showed that when the tumor suppressor gene VHL is inactivated by a mutation—a hallmark of clear cell renal cell cancer cells—these viruses in our genome (called endogenous retroviruses) are more likely to produce their proteins and that this process is driven by a human protein called HIF2, which is overabundant when VHL is crippled.

The team also found that the cancer cells break these viral proteins into fragments and present them on the cell surface as flags that have the potential to stimulate an immune response. Additional tests in human samples and in mice suggest that these flags can be detected by the immune cells called T cells and do stimulate an immune response against the cancer.

Evidence suggests that kidney cancer, unlike most other forms of cancer, is sometimes eradicated by the immune system. Exactly how is not well understood. This study suggests that the immune system can mount an attack on cancer cells that, due to the presence of cancer-driving mutations, present fragments of endogenous retroviral proteins on their surface. The discovery points to the potential for investigating new ways to leverage endogenous retroviruses in the development of novel immunotherapies.

Kidney cancer, renal cell carcinoma, tumor growth, nephrectomy, targeted therapy, immunotherapy, metastatic kidney cancer, oncogenes, tumor microenvironment, angiogenesis, renal biopsy, VEGF inhibitors, checkpoint inhibitors, genetic mutations, risk factors, early detection, survival rates, kidney cancer symptoms, renal oncology, clinical trials

#KidneyCancer, #RenalCellCarcinoma, #TumorGrowth, #Nephrectomy, #TargetedTherapy, #Immunotherapy, #MetastaticCancer, #Oncogenes, #TumorMicroenvironment, #Angiogenesis, #RenalBiopsy, #VEGFinhibitors, #CheckpointInhibitors, #GeneticMutations, #CancerRiskFactors, #EarlyDetection, #SurvivalRates, #CancerSymptoms, #RenalOncology, #ClinicalTrials

Comments

Post a Comment

Popular posts from this blog

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Post-Stroke Cardiovascular risks

Study finds genetic factors key to post-stroke cardiovascular risks In a recent study published in the journal Stroke , researchers identify genetic and molecular risk factors for subsequent cardiovascular outcomes after incident stroke in an effort to identify potential therapeutic targets to improve patient prognoses. Identifying the causes of stroke Stroke is a major global health issue that causes significant disability and mortality, particularly arterial ischemic stroke (AIS). AIS, which is a type of stroke caused by blocked blood flow to the brain, is responsible for up to 85% of stroke cases. AIS arises due to cerebral blood vessel blockage, with modifiable risk factors including hypertension, diabetes, dyslipidemia, atrial fibrillation, obesity, and lifestyle behaviors. Although genome-wide association studies (GWAS) often focus on incident strokes, studying subsequent events can provide new insights into stroke progression. Further research is crucial to identify genetic and...
Post a Comment
Read more

Type of Inherited Blindness in Dogs

Genetic test could eradicate a type of inherited blindness in dogs A mountain rescue dog whose duties ended after her eyesight failed has helped scientists create a test that could eradicate the genetic eye condition in her breed for good. Shola the English shepherd has an inherited eye disease called progressive retinal atrophy (PRA) that causes the light-sensitive cells at the back of the eye to deteriorate, eventually leading to blindness. PRA affects more than 100 dog breeds, can be caused by a number of different genetic variants and has no treatment. For some types, symptoms do not appear until the dog is several years old , by which point they may have passed their genes on to puppies. Katherine Stanbury, the first author of the research from the University of Cambridge, said Shola was four years old when she began struggling with her vision in dim light. “She was sent to a veterinary ophthalmologist and they confirmed that she had PRA,” said Stanbury. “And then it turned out h...
Post a Comment
Read more